The Investor
11 Aug 2026, 16:10
Abbott Partners With Google to Bring AI-Powered Glucose Insights to Everyday Health
Abbott (NYSE: ABT) announced a multi-year partnership with Google Health aimed at combining continuous glucose monitoring with artificial intelligence to provide more personalized health insights.
Under the partnership, glucose data from Abbott’s Lingo biowearable will be integrated into the Google Health app alongside other health and wellness information. Google Health Coach will use the data to generate personalized recommendations related to nutrition, physical activity, sleep and recovery.
The companies also plan to conduct what they describe as one of the largest real-world metabolic health studies, combining continuous glucose, wearable, laboratory and survey data. Findings are expected to help improve future AI coaching and Lingo features.
For Abbott, the agreement could broaden the role of its continuous glucose monitoring technology beyond traditional diabetes management. Lingo is an over-the-counter CGM designed for adults who do not use insulin, allowing users to track how factors such as food, exercise, sleep and stress affect glucose levels.
The collaboration also strengthens Abbott’s exposure to the growing intersection of wearable health technology and AI. Lingo integrations within Google Health are expected to begin rolling out later in 2026.
Abbott (NYSE: ABT) announced a multi-year partnership with Google Health aimed at combining continuous glucose monitoring with artificial intelligence to provide more personalized health insights.
Under the partnership, glucose data from Abbott’s Lingo biowearable will be integrated into the Google Health app alongside other health and wellness information. Google Health Coach will use the data to generate personalized recommendations related to nutrition, physical activity, sleep and recovery.
The companies also plan to conduct what they describe as one of the largest real-world metabolic health studies, combining continuous glucose, wearable, laboratory and survey data. Findings are expected to help improve future AI coaching and Lingo features.
For Abbott, the agreement could broaden the role of its continuous glucose monitoring technology beyond traditional diabetes management. Lingo is an over-the-counter CGM designed for adults who do not use insulin, allowing users to track how factors such as food, exercise, sleep and stress affect glucose levels.
The collaboration also strengthens Abbott’s exposure to the growing intersection of wearable health technology and AI. Lingo integrations within Google Health are expected to begin rolling out later in 2026.
